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Abstract
Background: Peroxynitrite is a cytotoxic oxidant formed
from nitric oxide (NO) and superoxide. Tyrosine nitration,
a footprint of peroxynitrite, has been demonstrated in the
pancreatic islets as well as in the cardiovascular system of
diabetic subjects. Delineation of the pathogenetic role of
peroxynitrite in disease conditions requires the use of po-
tent, in vivo active peroxynitrite decomposition catalysts.
The aim of the current work was to produce a potent per-
oxynitrite decomposition catalyst and to test its effects in
rodent models of diabetes and its complications.
Methods: FP15 was synthesized and analyzed using stan-
dard chemical methods. Diabetes was triggered by the
administration of streptozotocin. Tyrosine nitration was
measured immunohistochemically. Cardiovascular and vas-
cular measurements were conducted according to standard
physiologic methods.
Results: FP15, a potent porphyrinic peroxynitrite
decomposition catalyst, potently inhibited tyrosine ni-
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tration and peroxynitrite-induced cytotoxicity in vitro
and in vivo. FP15 treatment (3–10 mg/kg/d) dose de-
pendently and reduced the incidence and severity of di-
abetes mellitus in rats subjected to multiple low doses
of streptozotocin, as well as in nonobese mice develop-
ing spontaneous autoimmune diabetes. Furthermore,
treatment with FP15 protected against the development
of vascular dysfunction (loss of endothelium-dependent
relaxations) and the cardiac dysfunction (loss of my-
ocardial contractility) in diabetic mice. FP15 treatment
reduced tyrosine nitration in the diabetic pancreatic
islets.
Conclusions: The current results demonstrate the impor-
tance of endogenous peroxynitrite generation in the
pathogenesis of autoimmune diabetes and diabetic cardio-
vascular complications. Peroxynitrite decomposition cata-
lysts may be of therapeutic utility in diabetes and other
pathophysiologic conditions.
Introduction
Peroxynitrite, the cytotoxic reaction products of nitric
oxide (NO) and superoxide (1), acts as a terminal me-
diator of cellular injury in various pathophysiologic
conditions. Peroxynitrite is able to induce cell necro-
sis and apoptosis (1–5). Typical cytotoxic reaction
pathways triggered by peroxynitrite include lipid
peroxidation, DNA breakage and base modiﬁcation,
activation of the nuclear enzyme poly(ADP-ribose)
polymerase, as well as tyrosine nitration (1–8). Detec-
tion of this latter reaction is frequently being employed
as a footprint for the formation of peroxynitrite in vivo.
Tyrosine nitration has been demonstrated in a va-
riety of pathophysiologic conditions (9,10), including
diabetes mellitus (9–13). In the pancreatic islets of
spontaneous autoimmune diabetic mice, a signiﬁ-
cant increase in tyrosine nitration was found and the
degree of beta-cell destruction showed a good corre-
lation with the frequency of nitrotyrosine-positive
beta cells (10). It was therefore proposed that the 
intra-islet formation of peroxynitrite plays an active
pathogenic role in the pathogenesis of diabetes mel-
litus (10). The observation that nitrotyrosine forma-
tion is present in the cardiovascular system (heart
and blood vessels) of diabetic animals and humans
(11–13), coupled with the fact that exposure of
blood vessels of heart preparations to peroxynitrite
leads to vascular and cardiac dysfunction (14–17),
led to the suggestion that peroxynitrite may play an
active role in the pathogenesis of diabetic cardiovas-
cular failure. A direct demonstration of the patho-
genetic role of peroxynitrite requires pharmacologic
tools that have the ability to powerfully neutralize
peroxynitrite in vivo. Here we describe the synthesis
and characterization of FP15, a potent and in vivo
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active peroxynitrite decomposition catalyst. Using
FP15, we provide direct evidence for the patho-
genetic role of peroxynitrite in diabetic islet cell
destruction, as well as in diabetic cardiovascular
dysfunction.
Methods
Chemical Synthesis and In Vitro Characterization 
of the Compounds
Meso-tetra-2-pyridylporphyrin (2-PyP) was syn-
thesized from pyrrole and pyridine 2-carboxalde-
hyde or purchased from Mid-Century Chemicals.
Triethylene glycol monomethyl ether (95%), p-
toluenesulfonyl chloride (99%), triethylamine,
ammonium hexaﬂuorophosphate, ferrous ammo-
nium sulfate hexahydrate, and tetrabutylammonium
chloride were obtained from Aldrich. Dimethyl-
formamide, anhydrous titration grade, was obtained
from Acros. Sephadex LH-20 was purchased from
Amersham Pharmacia Biotech. Bio-Rad AG1X8 
ion-exchange resin (Cl form) was purchased from
Bio-Rad.
Synthesis of Triethylene Glycol Monomethyl Ether 
Tosylate Triethylene glycol monomethyl ether (5.0
g) was dissolved in 100 ml of freshly distilled
CH2Cl2 and 6.21 g (2 eq) triethylamine was added.
The reaction mixture was cooled in ice, and 7.55 g of
(1.3 eq) p-toluene sulfonyl chloride was added all at
once. The mixture was stirred overnight after the ice
melted. The reaction mixture was ﬁltered to remove
triethylamine hydrochloride and the solvent was
stripped. The residue was taken up in 75 ml ethyl
acetate, and it was washed with 75 ml sat NaHCO3,
then 75 ml 1 M KHSO4, then 75 ml sat NaHCO3. The
organic layer was dried over Na2SO4 and the solvent
was removed by distillation. The clear liquid
residue was chromatographed on silica gel in 3:7
EtOAc/CH2Cl2 to yield 7.05 g tosylate as a viscous
oil (73% yield). 1H NMR (CDCl3):  2.43 (s, 3 H,
PhCH3)  3.35 (s, 3H, OCH3)  3.50–3.53 (t, 2H,
CH3OCH2CH2)  3.57–3.61 (t, 2H, CH3OCH2CH2)
 3.56–3.59 (br s, 4H, -OCH2CH2-)  3.65–3.68 (t, 2H,
CH2CH2-OTs, J 4.6 Hz)  4.13–4.16 (t, 2H, CH2CH2-
OTs, J 4.6 Hz)  7.35–7.38 (d, 2H, aromatic, J 8.07)
 7.80–7.83 (d, 2H, aromatic, J 8.07).
Synthesis of Tetrakis-2-(Triethylene Glycol Monomethyl
Ether) Pyridyl Porphyrin To an oven-dried ﬂask un-
der argon was added 100 mg of meso-2-pyridyl por-
phyrin (Mid-Century), 2 g of tosylate, and 1.5 ml
of dry dimethylformamide. The mixture was heated
at 100 C for 2–3 days, until an aliquot of reaction
mixture partitioned between water and chloroform
showed no color in the chloroform layer. Complete
alkylation was conﬁrmed by the shift in maximum ab-
sorbance of the porphyrin from  412 to  418 nm.
The reaction mixture was cooled and added drop-
wise to stirred ether, and the porphyrin precipitated
as a purple gum. This gum was taken up in water, and
a saturated solution of ammonium hexaﬂuorophos-
phate added dropwise precipitated the porphyrin.
The hexaﬂuorophosphate salt could be precipitated
from acetone with tetrabutylammonium chloride to
yield the chloride salt of the porphyrin as a hy-
groscopic solid. It was puriﬁed by size exclusion
chromatography on Sephadex LH-20. Yields ranged
from 70–80%, and degree of alkylation was con-
ﬁrmed by electrospray mass spectrometry. 
1H NMR is complex, as four unresolvable atropiso-
mers form during alkylation. 
1H NMR (CD3OD):  3.0–3.6 (m, 13H, -OCH2CH2O-
and OCH3)  4.6–4.9 (m, 2H NCH2CH2O)  8.7
(m, 1 H, NCCH (m-pyridyl))  8.8–9.5 (br s, 4H, pyr-
role) d 9.0–9.2 (m, 2H, NCHCHCH, m-pyridyl and 
p-pyridyl) d 9.6–9.8 (m, 1H, NCH, o-pyridyl).
(UV-vis)
Synthesis of FeCl Tetrakis-2-(Triethylene Glycol
Monomethyl Ether) Pyridyl Porphyrin The iron metal-
lation process was modiﬁed from a procedure de-
scribed by Pasternack et al. (18). FP15 was dissolved
in water and 5 eq of ferrous ammonium sulfate was
added. The mixture was heated to reﬂux until the
Soret band broadened and max shifted from  418
to   412 nm. In addition, a broad shoulder ap-
peared at approximately   350 nm, which is
characteristic of an iron porphyrin, and the number
of Q-bands decreased from 4 to 2. The reaction mix-
ture was cooled, stirred with Bio-Rad AG1X8 ion-
exchange resin (Cl form) for 2 hr, then the resin
was ﬁltered off. The solution was neutralized after
ﬁltration with saturated NaHCO3. Solvent was
stripped and the residue was chromatographed on
Sephadex LH-20 In 1:1 CH3OH/H2O. Removal of
solvent left FP15 in 65% yield as a shiny black solid.
Time-Resolved Visible Spectra
All the time-resolved visible spectra were recorded
on a HI-TECH SF-61 DX2 stopped-ﬂow spectropho-
tometer equipped with a diode array detector (19).
The spectral resolution was about 1 nm. Reactions
between FP15 and peroxynitrite were single-
mixing experiments, performed at 25 C, and the
concentrations presented in all cases are the ﬁnal
concentrations after mixing. The porphyrin solutions
were buffered with 50 mM of phosphate buffer,
pH 7.4.
Nitration of Fluorescein
In a typical reaction, 5 M of ﬂuorescein in buffer is
reacted with 25 M of peroxynitrite in both the ab-
sence and presence of 5 M of FP15. The changes in
ﬂuorescein absorbance were measured on HP 8453
Uv-vis spectrophotometer, running HP Chemstation
software (Version A.07.01). The yield of nitration was
determined by converting absorbance to changes in
concentration of ﬂuorescein and nitrated ﬂuorescein,
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Induction of Diabetic Endothelial and 
Cardiac Dysfunction
For the cardiovascular studies, diabetes was induced
in male Balb/c mice by a single injection of strepto-
zotocin (200 mg/kg IV) (12). Mice developing severe
hyperglycemia (350 mg/dl) and glucosuria for 2
consequent days were selected and considered dia-
betic. Six weeks after the injection of streptozotocin,
control and diabetic mice received either vehicle or
FP15 (10 mg/kg/d orally in two divided doses). Di-
abetic mice and age-matched controls were killed
after 3 weeks after the start of FP15 treatment and
subjected to cardiovascular measurements. Analysis
of left ventricular performance was measured in
anesthetized mice with a Millar microtip catheter
transducer as described (22). For the measurement
of changes in vascular reactivity, an ex vivo thoracic
aorta assay was employed as described (14). In rings
precontracted with epinephrine (106 M), relaxation
to acetylcholine (109 to 105 M) and sodium nitro-
prusside (1012 to 105 M) was evaluated.
Data Analysis and Presentation
For the in vitro studies, all values in the ﬁgures and
text are expressed as mean  standard error of the
mean of n observations, where n represents the num-
ber of wells studied (6–9 wells from two or three 
independent experiments). Numerical data sets were
examined by analysis of variance and Bonferroni’s 
t-test. Diabetes incidence was compared using the
Chi-square test. A p-value less than 0.05 was consid-
ered statistically signiﬁcant.
Results
Chemical Characterization of FP15
We chose triethylene glycol monomethyl ether as the
N-alkylating group for 2-PyP because it satisﬁed the
requirements for bulk and hydrophilicity. Early at-
tempts to alkylate 2-PyP with triethylene glycol
monomethyl ether bromide or iodide were not suc-
cessful; the bromide and iodide were both difﬁcult
to synthesize and did not completely alkylate the
porphyrin. We synthesized the triethylene glycol
monomethyl ether tosylate, and this compound suc-
cessfully quaternized 2-PyP. The tosylate was also
much easier to synthesize, and consistent 70–80%
yields of pure product were obtained. 2-PyP was
alkylated in a hot mixture of DMF and tosylate, and
the reaction could be followed easily by UV-vis. The
Soret band of the porphyrin undergoes a charac-
teristic shift from  412 to  418 nm upon 
complete alkylation. The tosylate counterions are
exchanged for chloride by double precipitation with
ammonium hexaﬂuorophosphate and then tetra-
butylammonium chloride. The porphyrin thus ob-
tained, tetrakis 2-(triethylene glycol monomethyl
ether) pyridyl porphyrin (2-T(PEG3)PyP) could be
characterized by 1H NMR and electrospray mass
spectrometry.
using predetermined extinction coefﬁcients. For in-
creased accuracy, the three wavelengths where the
largest changes in absorbance occur were used.
Also, because the catalyst is bleached to a small
extent by peroxynitrite (1% delta OD), the ab-
sorbance measurements of ﬂuorescein were adjusted
for this small change in the absorbance of the cata-
lyst during the reaction. The yields were calculated
based on the initial substrate concentration.
Testing of FP15 in Cell Culture
The RINm5F insulin-containing beta-cell line (RIN)
and the human umbilical vein endothelial cells
(HUVEC) were cultured in 96-well plates until con-
ﬂuence as described (14,20). The RIN cells were
selected because they are relevant for the primary
process of diabetes, the HUVEC cells because of
their relevance for cardiovascular dysfunction. In
addition, primary mouse thymocytes, a convenient
model system for peroxynitrite-induced cell necrosis
and apoptosis, were also used as previously de-
scribed (5). Cells were then exposed to peroxynitrite
(50–600 M) in the presence or absence of a 10-min
pretreatment with FP15 (3–30 M).
Quantiﬁcation of Cell Death
Mitochondrial respiration, a global index of cell 
viability, was assessed by the reduction of 3-(4,
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) to formazan as described (14). In thymo-
cytes, apoptosis and necrosis were simultaneously
measured by the quantiﬁcation of annexin staining
and cellular propidium iodide uptake using ﬂow cyto-
metry as described (5).
Multiple Low-Dose Streptozotocin Model of Diabetes
Male BALB/c mice were treated with streptozotocin
(40 mg/kg) or vehicle (citrate buffer) IP for 5 con-
secutive days (21) in the presence or absence of
FP15 (3 or 10 mg/kg/d orally in two divided doses)
starting on day 1. Blood glucose was measured on
days 1, 7, 14, and 21 from blood obtained from the
tail vein using a one-touch blood glucose meter.
Hyperglycemia was deﬁned as nonfasting blood
glucose 200 mg/dl. Samples of pancreas were re-
moved and analyzed for insulin, malon dialdehyde,
and myeloperoxidase content, an indicator of neu-
trophil inﬁltration as described (21). Furthermore,
pancreas sections were excised, ﬁxed in 10% formal-
dehyde, and immunohistochemically analyzed for
nitrotyrosine formation (10,12).
Development of Diabetes in the Nonobese Diabetic Mice
Female nonobese diabetic (NOD) mice develop a
high incidence of diabetes between the 10th and
25th weeks of life (12). We have subjected groups
of NOD mice to vehicle or FP15 treatment (3 and
10 mg/kg, treatment protocols identical to the
streptozotocin model) between the ages of 10 and
25 weeks.
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Kinetics of Catalytic Peroxynitrite Decomposition by FP15
FP15 (0–8 M) in PBS pH 7.4 was reacted with
100 M of peroxynitrite in a rapid-mixing stopped
ﬂow spectrophotometer as described (17) in PBS pH
7.4 in the absence or presence of 10 mM of bicarbon-
ate. The rate constant of peroxynitrite decay was de-
termined by ﬁtting the 302-nm data to a ﬁrst-order
rate expression. The results were plotted versus the
catalyst concentration (Fig. 1). The shape of the rate
constant dependence on the catalyst concentration is
nonlinear and upward sloping, as observed before for
other FeTMPyP-based porphyrins (23). The data in-
dicated that the contribution of CO2-catalyzed perox-
ynitrite decomposition to its overall decay decreases
at higher catalyst concentrations. In fact, at 8 M of
catalyst, the presence of 10 mM of bicarbonate has no
measurable effect on peroxynitrite decay. This effect
is explained by the fact that under these conditions,
FP15 outcompetes the reaction with carbon dioxide.
Only 5% of all peroxynitrite reacted with carbon
dioxide and 95% reacted with the catalyst, which at
this concentration has a second-order rate constant of
6.25  106 M1 s1.
Inhibition of Phenolic Nitration by FP15
Nitration of ﬂuorescein by peroxynitrite can be used
as a sensitive marker for the efﬁciency of phenolic
nitration. Catalysts that can rapidly decompose per-
oxynitrite without creating nitrating species will
reduce the level of ﬂuorescein nitration when pre-
sent in micromolar amounts. The results showed
that the presence of 5 M of FP15 decreases the level
of ﬂuorescein nitration by peroxynitrite approxi-
mately 8-fold (Table 1). Also, the presence of 10 mM
of bicarbonate, which reacts relatively fast with per-
oxynitrite to form peroxynitritocarbonate (a very
reactive and unstable intermediate that rapidly
decomposes and forms carbonate and nitrate radi-
cals), has very small effect under these conditions.
Cytoprotection by FP15 In Vitro
Exposure of islet cells, endothelial cells, and thymo-
cytes to peroxynitrite induced a dose-dependent cyto-
toxicity, with the thymocytes and the islets being
most sensitive (Fig. 2). Pretreatment of the cells with
FP15 (3–30 M) caused a dose-dependent restoration
of cell viability and of the mitochondrial respiration
(Fig. 2A). FP15 treatment protected both against per-
oxynitrite-induced necrosis and apoptosis, as shown
in thymocytes by ﬂow cytometric analysis (Fig. 2B).
Role of Peroxynitrite in the Process of Islet Cell Destruction
and Diabetes Development
Because evidence for the formation of peroxynitrite
has previously been reported in diabetic islets (12),
now we tested whether treatment of streptozotocin-
diabetic mice with FP15 ameliorates the incidence
and severity of diabetes. Oral treatment with FP15
provided a dose-dependent, and—at the highest
dose of 10 mg/kg used—near-complete protection
against hyperglycemia, pancreatic beta cell destruc-
tion, and diabetes incidence in the multiple low-
dose streptozotocin diabetes (Fig. 3). The effects of
FP15 were associated with suppression of pancreatic
malon dialdehyde levels, consistent with a reduced
oxidative stress in the pancreas (e.g., 10 mg/kg FP15
reduced malon dialdehyde levels in diabetic islets
from 653  54 to 312  37 pmol/mg protein, p 0.01,
n 8; baseline levels amounted to 258  42 pmol/mg
protein in nondiabetic mice). Myeloperoxidase lev-
els, an indicator of neutrophil inﬁltration, were un-
affected by FP15 treatment (data not shown). FP15
treatment attenuated the tyrosine nitration in the 
diabetic islets (Fig. 4).
Fig. 1. Determination of kcat of FP15 toward peroxynitrite
decomposition. Reaction was carried out in PBS pH 7.4 in the
absence (closed square) or presence (closed diamond) of 10 mM
of bicarbonate. Concentration of FP15 was varied 0–8 M, per-
oxynitrite was maintained at 100 M. FP15 concentration
was plotted against the observed rate constant of peroxynitrite
decay. Kobs is obtained from ﬁrst-order ﬁt of absorbance decay
at 302 nm. The plot shows a nonlinear dependence that sug-
gests involvement of two distinct reaction pathways, as pro-
posed elsewhere (19).
Table 1. Reduction of tyrosine nitration by FP15 
in vitro
0.1 M PBS, 0.1 M PBS,
pH 7.4 10 mM HCO3,
(I  0.26 M) pH 7.58, (I  1.0 M)
No Catalyst 41.9% 55.1%
Exp. 1 4.9% 5.7%
Exp. 2 6.5% 5.6%
Exp. 3 5.0% 5.2%
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the development of endothelial dysfunction and
diabetic cardiac dysfunction. In these experiments,
a single high-dose streptozotocin was used in
rats. This protocol is most suitable for the sudden,
complete destruction of diabetic islets and pro-
duces a rapid-onset, prolonged hyperglycemia (12).
Six weeks after the injection of streptozotocin,
control and diabetic mice began either vehicle or
FP15 (10 mg/kg/d orally) treatment, and were
killed 3 weeks later. This delayed start of perox-
ynitrite decomposition catalyst treatment ensured
that the animals received the FP15 treatment at a
time when islet cell destruction was already com-
plete and hyperglycemia has stabilized. In this
way, we avoided interference of the compound
with the primary process of the islet cell destruc-
tion, as conﬁrmed by a lack of effect of FP15
on blood glucose concentration in this posttreat-
ment regimen. Although FP15 did not affect blood
glucose levels, it provided a marked protection
against the loss of endothelium-dependent relax-
ant ability of the blood vessels (Fig. 5). No dif-
ferences were seen in the degree of sodium
Although the multiple low-dose streptozotocin
(MLDS) model has a component of immune/in-
ﬂammatory injury, as well as a chemical (direct ox-
idant) component, we sought to conﬁrm the effects
using another model system, which is generally
considered closer to the human autoimmune Type I
diabetes. NOD mice provide such a model; the
female animals are genetically predisposed and
develop diabetes over time. Oral treatment with
FP15 provided a marked, signiﬁcant protection
against diabetes onset in the NOD model. For
example, at week 25, diabetes incidence stabilized
at 14/18 in the vehicle treated group (78%),
whereas it was reduced to 4/18 (22%) in the FP15
(10 mg/kg/d) treated group (n  18 animals per
group, p  0.05).
Role of Peroxynitrite in the Development of Diabetic
Cardiovascular Complications
The formation of peroxynitrite has previously been
reported in blood vessels and hearts of diabetic
subjects (10–13). Therefore, we tested whether
treatment of diabetic mice with FP15 ameliorates
Fig. 2. Cytoprotection by FP15.
(A) Effect of peroxynitrite (50–600
M) on mitochondrial respiration in
RINm5F cells (left panel) and HU-
VECs (right panel); concentration-de-
pendent restoration of the suppres-
sion of mitochondrial respiration by
FP15 (3–30 M). *,** represent sig-
niﬁcant effects of FP15 in peroxyni-
trite-treated cells (p  0.05, p  0.01,
respectively); n  6 to 9. (B) Cytoﬂu-
orometric analysis of thymocyte
necrosis and apoptosis induced by
peroxynitrite. Thymocytes were
treated for 4 hr with 20–80 M of
peroxynitrite. Cells were then stained
with Annexin V-FITC and propidium
iodide (PI) and two-color analysis
was performed by ﬂow cytometry.
During apoptosis, phosphatidylserine
becomes exposed on the outer surface
of the plasma membrane and can be
detected by Annexin-FITC. Necrosis
is characterized by the breakdown of
plasma membrane integrity that can
be measured by the uptake of the cell
impermeable dye propidium iodide
(5). An increase in the number of
apoptotic (Annexin V-FITC single
positive, bottom right quadrant) cells
as well as necrotic (stained by both
Annexin V-FITC and PI, top right
quadrant) cells was observed in re-
sponse to 20-M peroxynitrite treat-
ment, whereas necrotic cells dominate
in response to 80-M peroxynitrite.
FP15-treated cells were protected
against both necrotic and apoptotic
cell death, and normal cells (bottom
left quadrant) are predominant. Simi-
lar results were found in four inde-
pendent experiments.
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nitroprusside-induced endothelium-independent
relaxations between experimental groups (data
not shown). Diabetes was also characterized by an
increase in left ventricular end-diastolic pressure and
decrease in heart rate, mean blood pressure, left
ventricular systolic pressure, dP/dt, and dP/dt
(Fig. 6). FP15 improved the depression in left ven-
tricular systolic pressure and diastolic dP/dt. More-
over, the elevation of the left ventricular end-diastolic
pressure and the decrease of systolic dP/dt were
prevented by the peroxynitrite decomposition cata-
lyst inhibitor treatment. FP15 in nondiabetic rats had
no signiﬁcant effects on vascular responsiveness or
hemodynamic parameters (Figs. 5 and 6).
Discussion
FP15, A Porphyrinic Peroxynitrite Decomposition Catalyst,
Protects Against Peroxynitrite-Induced Cytotoxicity
The chemistry and biology of peroxynitrite have
been under intense scrutiny since its cytotoxic ac-
tivity (23–29) was ﬁrst recognized. This molecule
has been implicated in many pathophysiologic
conditions, and it has been shown that the body’s
own systems are ill-equipped to eliminate it (see
Introduction and Shi et al. [30]). Metallopor-
phyrins are of particular interest for this reason;
peroxynitrite reacts very efﬁciently with biological
metal centers (18,31–33). If a metalloporphyrin
could be introduced into a living system as treat-
ment for peroxynitrite injury, it would be of thera-
peutic potential. It has recently been shown that
certain water-soluble manganese and iron porphyrins
show high rates of reaction with peroxynitrite (29).
Fig. 3. Dose-dependent effect of FP15 on (top panel) 
hyperglycemia and (bottom panel) diabetes incidence in
male BALB/c mice following treatment with multiple
low-dose streptozotocin (MLDS, 18 mice per experimental
group). *p  0.05 and **p  0.01 in diabetic versus untreated
(nondiabetic) mice and †p  0.05 in FP15 treated diabetic mice
versus vehicle-treated diabetic mice.
Fig. 4. Nitrotyrosine immunostaining in the multiple low-
dose streptozotocin diabetes model in (A) the pancreas of
a control (nondiabetic) mouse, (B) pancreas of a mouse at
14 days of diabetes, and (C) pancreas of an FP15-treated
mouse at 14 days of diabetes. Note the marked increase in ni-
trotyrosine staining in the islets in diabetes, and its ameliora-
tion in the FP15-treated animals. Pictures representative of n 
4 to 5 experiments are shown. Original magniﬁcation: 40.
Fig. 5. Reversal of diabetes-induced endothelial dysfunc-
tion by FP15 in vascular rings from STZ-diabetic mice.
Ach-induced endothelium-dependent relaxation is impaired in
rings from diabetic mice, which is markedly improved by
FP15 treatment. Each point of the curve represents the mean 
SEM of 5–7 pairs of experiments in vascular rings. *p  0.05
in FP15 treated diabetic mice versus vehicle-treated diabetic
mice.
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postulates the involvement of an oxoFe(IV) interme-
diate in a separate catalytic pathway. The data also
indicate that the contribution of CO2-catalyzed
peroxynitrite decomposition to its overall decay de-
creases at higher catalyst concentrations. In fact, at
8 M of catalyst, the presence of 10 mM of bicar-
bonate has no measurable effect on peroxynitrite de-
cay. This effect is explained by the fact that under
these conditions, FP15 outcompetes the reaction
with carbon dioxide. Only 5% of all peroxynitrite
reacted with carbon dioxide and 95% reacted with
the catalyst, which at this concentration has a 
second-order rate constant of 6.25  106 M1 s1. As
was shown in the stopped ﬂow experiment, dis-
cussed above, at this catalyst concentration, FP15 
reacts with peroxynitrite at an approximate second-
order rate constant of 3.5  106 M1 s1, whereas the
corresponding rate constant between carbon dioxide
and peroxynitrite is 3  104 M1 s1 (35). Under
these conditions the concentration of aqueous car-
bon dioxide is only 0.23 mM, so the ﬂux of perox-
ynitrite reacting with it instead of with FP15 is ap-
proximately 13%, whereas the ﬂux through FP15 is
86%, and only about 0.4% of peroxynitrite decom-
poses spontaneously. The fact that FP15 decomposes
peroxynitrite directly to nitrate without producing
nitrating intermediates, as has been suggested for its
analogs (21), is supported by the current ﬁndings
showing that the nitration of ﬂuorescein is inhibited
in its presence. The above rough calculation of per-
oxynitrite ﬂux illustrates that because only 13% of
peroxynitrite reacts with carbon dioxide, which in
absence of catalyst gives 55% nitration, then the ex-
pected nitration yield in the presence of FP15 would
be 7%, which is very similar to the experimentally
obtained nitration yield.
Just like with other porphyrins and antioxi-
dants, additional redox properties of the compound
on other oxidant species (superoxide, hydrogen per-
oxide, nitroxyl anion, etc.) are possible. These addi-
tional actions may limit the speciﬁcity of the com-
pound, and may reduce its utility as a tool to dissect
peroxynitrite-mediated pathogenetic processes from
processes triggered by these above-mentioned oxi-
dants. On the other hand, such additional actions
may extend the therapeutic utility of these agents.
Role of Peroxynitrite in the Pathogenesis of Diabetic Islet
Cell Destruction and Hyperglycemia
As discussed in the Introduction, tyrosine nitration
has been previously reported in diabetic islets, and its
degree showed a good correlation with the degree of
diabetes. In addition, it was previously reported that
human islets are extremely sensitive to peroxynitrite
toxicity (36). NO synthase inhibitors and the in-
ducible NO synthase knockout mice are protected
against diabetes development (37,38). The current re-
port is the ﬁrst one to directly demonstrate that a per-
oxynitrite decomposition catalyst ameliorates disease
onset and severity, both in a combined chemically
One such porphyrin, iron(III) meso-tetrakis(2,
4,6-trimethyl-3,5-disulfonato) porphine chloride
(FeTMPS) has already shown activity at micromolar
levels and was shown to attenuate carrageenan-
induced paw edema in rats (34). This result, com-
bined with the attractive peroxynitrite turnover
rates obtained for the family of pyridyl porphyrins,
prompted us to consider a new catalyst based on
the pyridyl porphyrin systems.
The novel catalyst FP15 represents an effort to
apply results obtained in vitro to biological systems.
This catalyst has been designed speciﬁcally for phar-
macologic use, building on previous knowledge in
the ﬁeld for maximum efﬁcacy. The polyethylene
glycol chains attached to the porphyrin provide a
hydrophilic environment for peroxynitrite while
providing sufﬁcient bulk to hinder deleterious asso-
ciations between the porphyrin and DNA. It retains
the high rate constant for peroxynitrite turnover ob-
served for other iron porphyrin catalysts (17,21),
showing that diverse groups may be introduced at
the N-pyridyl position and the porphyrin will still
retain activity. The shape of the rate constant depen-
dence on the catalyst concentration is nonlinear and
upward sloping, and has been observed before for
other FeTMPyP-based porphyrins (21). This pecu-
liar curvature gave rise to a reaction mechanism that
Fig. 6. Reversal of streptozotocin-evoked diabetes-
induced diastolic cardiac dysfunction by FP15 in mice. 
Effect of diabetes (9–10 weeks) and FP15 treatment in diabetic
mice on left ventricular end diastolic pressure (LVEDP) and left
ventricular dp/dt (LV dp/dt). Results are mean  SEM of
seven experiments in each group. *p  0.05 diabetic animals
versus control; #p  0.05 in FP15-treated diabetic mice versus
vehicle-treated diabetic mice.
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induced/autoimmune model (the multiple low-dose
streptozotocin model) and in the autoimmune mode
(NOD mice). Although peroxynitrite has been re-
ported to induce neutrophil adhesion and activation
in vitro (39), we did not ﬁnd evidence for suppressed
neutrophil inﬁltration into the pancreas in FP15-
treated diabetic mice. This ﬁnding is consistent with
ﬁndings obtained with an earlier generation perox-
ynitrite decomposition catalyst, 5,10,15,20-tetrakis-
[4-sulfonatophenyl]-porphyrinato-iron (FeTPPS) in a
rat model of splanchnic occlusion-reperfusion injury,
where reduced lipid peroxidation, but no change in
myeloperoxidase levels, was observed (40).
Role of Peroxynitrite in the Pathogenesis of Diabetic Islet
Cell Destruction and Hyperglycemia
The agonist-induced release of NO from the vascular
endothelium plays a crucial role in maintaining the
vascular homeostasis by keeping the blood vessels in
a constant state of vasodilatation and by preventing
platelet and mononuclear cell deposition to the in-
tima. Impairment of the endothelial function has
been proposed to predispose to a variety of vascular
diseases, including diabetic micro- and macroan-
giopathy (12). Exposure of blood vessels to peroxyni-
trite can lead to an impairment of the endothelium-
dependent relaxant ability (14). The present study
provides direct evidence for the pathogenic role of
peroxynitrite in diabetic endothelial dysfunction. The
peroxynitrite decomposition catalyst was effective in
this model despite the fact that the blood vessels were
exposed to continuous, high levels of circulating glu-
cose. In this diabetes model, a complete diabetic en-
dothelial dysfunction develops by 4 weeks (12,41).
Thus, the compound not only is able to prevent the
development of diabetic endothelial dysfunction, but
is also able to restore the function of diabetic blood
vessels with established endotheliopathy. The mech-
anism by which FP15 protects diabetic blood vessels
from endothelial dysfunction may involve protection
against vascular tyrosine nitration, PARP activation,
lipid peroxidation, and multiple other mechanisms;
all these mechanisms have previously been linked to
diabetic vasculopathy as well as to peroxynitrite-
induced vascular injury (2–14).
Role of Peroxynitrite in the Pathogenesis 
of Diabetic Cardiomyopathy
Diabetic cardiomyopathy is characterized by com-
plex changes in the mechanical, biochemical, struc-
tural, and electrical properties of the heart, which
may be responsible for the development of an early
diastolic dysfunction and increased incidence of
cardiac arrhythmias in diabetic patients (42). The
present study demonstrates that streptozotocin-
induced diabetes in NOD mice and rats was asso-
ciated with a marked depression of left ventricular
function involving both systolic pressure devel-
opment and relaxation. Importantly, the results pre-
sented here document for the ﬁrst time that the
impaired diabetic cardiac function can be reversed
by pharmacologic neutralization of peroxynitrite
toxicity.
Oxidative stress associated with an impaired an-
tioxidant defense status may play a critical role in
subcellular remodeling, calcium-handling abnor-
malities, and subsequent diabetic cardiomyopathy
(42). Consistent with this idea, signiﬁcant nitrotyro-
sine formation was reported in cardiac myocytes
from myocardial biopsy samples obtained from
diabetic and diabetic-hypertensive patients (43) and
in a mouse model of streptozotocin-induced dia-
betes (44). The present study provides direct evi-
dence for the pathogenetic role of peroxynitrite in the
development of the contractile function in the heart.
The mechanism by which FP15 protects diabetic
hearts from dysfunction may involve protection
against vascular and myocardial tyrosine nitration,
PARP activation, lipid peroxidation, and multiple
other mechanisms; all these mechanisms have pre-
viously been linked to diabetic cardiomyopathy
as well as to peroxynitrite-induced cardiac injury.
Additional mechanisms of peroxynitrite-mediated
diabetic cardiac dysfunction may include inhibition
of myoﬁbrillar creatine kinase (45) and of succinyl-
CoA:3-oxoacid CoA-transferase (46).
Conclusions and Implications
The current studies describe the synthesis and char-
acterization of FP15, a potent novel peroxynitrite de-
composition catalyst. Treatment of diabetic animals
with FP15 demonstrated the involvement of perox-
ynitrite in the pathogenesis of the primary disease,
as well as in the development of vascular and my-
ocardial dysfunction. Additional studies demon-
strate the neuroprotective (47) and cardioprotective
(48,49) effects of FP15, as well as its potent beneﬁ-
cial effects in lung reperfusion models (50) and in
murine models of rheumatoid arthritis and inﬂam-
matory bowel disease (51). The current results sup-
port the view that peroxynitrite-neutralizing agents
may be of interest in the experimental therapy of
various pathophysiologic conditions associated with
peroxynitrite generation.
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